|
|
|
|
||
Re: Excerpt from Barclays Weekly Biotech SMID Cap ReportNo question a distinct possibility. When a legitimate offer is presented many factors are weighed and shareholder benefit should be the number one consideration. Having given and received lucrative offers I can tell you they move mountains. |
return to message board, top of board |